NPM1 and myelodysplastic syndrome: This is in agreement with a recent retrospective study of 257 patients with NPM1-mutated AML showing that MDS-related mutations (therein termed ‘secondary-type’ mutations) have no impact on patient outcomes, suggesting that it is solely the NPM1 gene mutation driving the disease biology [22].